The US Food and Drug Administration (FDA) has registered Swiss diagnostic solutions provider Abionic’s abioSCOPE testing platform and rapid allergy test, IVD CAPSULE Aeroallergens.

Common respiratory allergies can be tested on the new diagnostic platform with a single drop of blood, eliminating the need for multiple visits and invasive tests.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The testing platform, which features a fully automated fluorescent microscope, uses nanotechnology and diffusion phenomena to form specific molecular complexes that are detected through an integrated laser.

In addition to common grass and tree pollens, the IVD CAPSULE Aeroallergens test can be used to find out patient’s sensitisation to major allergens from cats and dogs.

The new technology enables allergy experts to quickly evaluate the reason for trigger of allergic symptoms, aiding in optimised disease management.

“We hope to bring new treatment options to patients where significant unmet medical need remains.”

Abionic CEO Dr Nicolas Durand said: “The FDA registration for the abioSCOPE and our first allergy test is a major milestone for Abionic and an important regulatory step that sets the stage for commercialisation and a staged market entry of this revolutionary technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We can now look to offer a rapid, easy-to-use testing platform, providing allergy sufferers a more convenient and time efficient testing experience.”

Upon testing blood samples from allergic and non-allergic subjects, abioSCOPE with IVD CAPSULE Aeroallergens was found to be rapid when compared to traditional laboratory method.

abioSCOPE is reported to have detected quantitative IgE antibody levels to four allergens of the test during a total assay time of eight minutes, with the first result delivered in five minutes.

The firm plans to begin commercialisation of the allergy test in the country next year and is seeking relevant partners for distribution.